血管活性剂疗法在败血性休克:从单疗法战斗到量身定制的血液动力学优化
Mingyang Zhu1, Yuxiang Zhang1, Wenming Liu1,2
1Nanjing Medical University, Nanjing, China.
Shock (Augusta, Ga.)
|December 28, 2025
概括
管理败血性休克包括稳定血液动力学和确保器官输液. 最近的研究表明,从经验转向目标导向的血管压缩剂疗法,改善了患者的治疗结果.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 生理学 生理学 生理学
背景情况:
- 败血冲击管理优先考虑血液动力学稳定和器官 perfusion.
- 液体复苏和血管活性剂对于创建治疗窗口至关重要.
- 活下来的败血症运动指导优化血管活性剂策略.
研究的目的:
- 为了审查血管压缩剂治疗在25年来感染性休克的演变.
- 综合传统药物和"脱 катехо化"策略的证据.
- 探索未来的方向,包括人工智能和基因组医学.
主要方法:
- 文献综述综合了过去25年的关键研究.
- 分析从经验主义转向目标导向的血管压力器战略的范式转变.
- 检查正在发展的器官 perfusion 和保护的概念框架.
主要成果:
- 从经验到目标导向的血管压缩剂疗法发生了重大转变.
- 更好地了解血管活性剂的益处风险概况.
- 管理的进步从血液动力学参数到综合护理包,监测器官 perfusion,微循环和氧化代谢.
结论:
- 管理策略已经向组合和多模式治疗概念发展.
- 对传统药物的重新评估和对"脱甲胺化"的探索扩大了治疗领域.
- 人工智能和基因组医学已经准备好个性化败血栓冲击管理.
关键词:
败血症的冲击是一个令人震惊的结果.脱卡特科化 (de-catecholaminization) 是一种脱卡特科化过程.多模式疗法多模式疗法组织 perfusion perfusion 组织 perfusion 组织 perfusion 组织 perfusion 组织 perfusion 组织 perfusion 组织 perfusion 组织 perfusion 组织 perfusion血管活性剂 血管活性剂更多相关视频
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
1.4K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.4K
Heart Failure V: Medical Management
196
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
Heart Failure VI: Adjunct Therapies
233
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
418
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
418
Hypertension IV: Drug Therapy and Lifestyle Modifications
564
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
564
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
549
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
549


